about
Retinoid receptor-specific agonists alleviate experimental glomerulonephritisPharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.DR(high+)CD45RA(-)-Tregs potentially affect the suppressive activity of the total Treg pool in renal transplant patients.The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEntsDevelopment of a standardized knowledge base to generate individualized medication plans automatically with drug administration recommendationsThe role of age-related T-cell differentiation in patients with renal replacement therapy.Cell therapeutic approaches to immunosuppression after clinical kidney transplantation.Psychosocial and physical outcome following kidney donation-a retrospective analysis.Cellular infiltrates and NFκB subunit c-Rel signaling in kidney allografts of patients with clinical operational tolerance.An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.The Case: Renal failure in a male with Waldenström's macroglobulinemia.Isotretinoin alleviates renal damage in rat chronic glomerulonephritis.The success of assisted reproduction technologies in relation to composition of the total regulatory T cell (Treg) pool and different Treg subsets.Retinoid agonist isotretinoin ameliorates obstructive renal injury.Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat.What, if all alerts were specific - estimating the potential impact on drug interaction alert burden.The extent of HLA-DR expression on HLA-DR(+) Tregs allows the identification of patients with clinically relevant borderline rejection.Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats.Chronic low-dose isotretinoin treatment limits renal damage in subtotally nephrectomized rats.Correction: Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts.Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.Aberrant ICOS+ -T cell differentiation in women with spontaneous preterm labor.Differentiation of ICOS+ and ICOS- recent thymic emigrant regulatory T cells (RTE T regs) during normal pregnancy, pre-eclampsia and HELLP syndrome.The role of recent thymic emigrant-regulatory T-cell (RTE-Treg) differentiation during pregnancy.High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis.Clostridium difficile diarrhoea in the immunosuppressed patient--update on prevention and managementPregnancy-associated diseases are characterized by the composition of the systemic regulatory T cell (Treg) pool with distinct subsets of TregsUremia aggravates left ventricular remodeling after myocardial infarctionHenoch-Schönlein purpura in adults is not uncommon in elderly patients with an adverse prognosisIn renal transplants with delayed graft function chemokines and chemokine receptor expression predict long-term allograft functionA distinct subset of HLA-DR+-regulatory T cells is involved in the induction of preterm labor during pregnancy and in the induction of organ rejection after transplantationMethylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients
P50
Q28571178-2150A709-E82C-4889-9695-1EE1CB4B9A1EQ33764989-8329CE47-5D6A-42C1-8DA4-44EE0652495BQ34217788-24B05001-9E47-484B-89EB-CAF872EA5CC8Q34995106-DC7B6921-BD5B-4690-91CA-B039769C0299Q36633951-ECD6EC30-F481-4BC6-86C2-D73C141AEE65Q37193978-FC224D7D-2486-405A-BA38-D2CD54B1B62BQ38672633-6B3845A5-6F51-4251-BDF5-4DE1AEC8D8A8Q38754342-9F87867F-22E5-4FA5-AB4F-1B2DB0EF2C2EQ39064811-9B3BE6C0-89F8-46E3-98B3-94E59422052CQ40061366-0C792109-83CA-44B0-8057-A6B02E0A22F2Q40220124-0C536589-F5D6-4DD0-97CF-17A0E6146F2EQ42952176-0C50EF9D-8E14-45AF-9AEC-7DDC4438A901Q43179204-F8C9A004-AD3E-4C7D-81EA-EF66B17FA527Q43818221-4C6FBC43-8030-47E3-855D-F7F53577FECDQ44381094-6EE869CC-D30A-49AF-9F3B-CB9CD0C24570Q44591408-FE1FCE39-05ED-4520-907B-FCAA2A1EB756Q44719769-4B6D0DCB-64A5-48AA-8A84-0C7B74EC64F1Q45333308-12F91950-2462-4D2A-866B-67AB2CF5EB50Q45342464-F70BA747-3033-4A23-9422-BE67B53EEB5BQ45964961-8DBC024C-F45D-426F-B06D-5969BFA3F1EFQ46087527-23AEADB6-1E96-4550-83F1-3A1BA1F60A68Q46364787-028C4B92-3622-4A1D-B215-5577981F81B6Q46468617-9664A712-C377-46AA-A5ED-57EF18FD11A1Q48329048-20E86861-B047-4E4C-BB2E-2F03CA5747BEQ50624162-181D4751-2175-4C18-809F-2677906C9BC7Q50715033-BA5B6C18-4BD4-41A4-976C-9DD9C9F7E2B3Q50738671-DA3DF7E1-234C-4B88-923A-B54B55A47D2AQ53566637-1399D55D-402A-4ECD-95DD-F45F417E7FE9Q80389135-D0A03050-FCAB-49C7-B789-CC595C07826BQ82761026-0F507392-BC34-46AE-A045-95EE61CDA31DQ84258935-CA808162-969F-46CA-8CAA-433B69C874D8Q84488906-935E9B09-3F04-496C-97B6-DA50C620BA76Q84706882-A4A9B594-F0E4-490E-A786-5680ABA4B15EQ84993446-98AE3A87-3D6D-4B2D-807B-BBC9832961F7Q87395242-DEB242B2-6C03-433D-8EF7-2AE469C88604
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Matthias Schaier
@ast
Matthias Schaier
@en
Matthias Schaier
@es
Matthias Schaier
@nl
Matthias Schaier
@sl
type
label
Matthias Schaier
@ast
Matthias Schaier
@en
Matthias Schaier
@es
Matthias Schaier
@nl
Matthias Schaier
@sl
prefLabel
Matthias Schaier
@ast
Matthias Schaier
@en
Matthias Schaier
@es
Matthias Schaier
@nl
Matthias Schaier
@sl
P214
P106
P21
P214
P31
P496
0000-0003-1040-1150
P735
P7859
viaf-77381882